Giuseppe Auteri

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio et al. · Cancer · 2019 · 144 citations · Full text

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

Francesca Palandri, Elena Rossi, Daniela Bartoletti et al. · Blood · 2021 · 53 citations · Full text

Eltrombopag second‐line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off‐treatment: results of a phase II, multicentre, prospective study

Elisa Lucchini, Francesca Palandri, Stefano Volpetti et al. · British Journal of Haematology · 2021 · 47 citations

Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome

Francesca Palandri, Massimo Breccia, Camilla Mazzoni et al. · Cancer · 2023 · 36 citations · Full text

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

Nicola Polverelli, Elena Maria Elli, Elisabetta Abruzzese et al. · British Journal of Haematology · 2020 · 34 citations · Full text